Article Information
History
- July 7, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Dan H. Barouch, MD PhD1,*,
- Kathryn E. Stephenson, MD MPH1,
- Jerald Sadoff, MD2,
- Jingyou Yu, PhD1,
- Aiquan Chang, MS1,
- Makda Gebre, MS1,
- Katherine McMahan, BS1,
- Jinyan Liu, PhD1,
- Abishek Chandrashekar, MS1,
- Shivani Patel, BS1,
- Mathieu Le Gars, PhD2,
- Anne Marit de Groot, PhD2,
- Dirk Heerwegh, PhD3,
- Frank Struyf, MD3,
- Macaya Douoguih, MD2,
- Johan van Hoof, MD2 and
- Hanneke Schuitemaker, PhD2
- 1Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
- 2Janssen Vaccines & Prevention, Leiden, The Netherlands
- 3Janssen Research & Development, Beerse, Belgium
- ↵*Corresponding Author: Dan H. Barouch, M.D.; Email: dbarouch{at}bidmc.harvard.edu
Posted July 07, 2021.
Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
